MedTrace Logo

Inhaled NAC in Treatment of IPF

NCT03720483 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2021-06-08

No results posted yet for this study

Summary

This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

N-acetyl cysteine then Placebo

Subject will receive N-acetyl cysteine first followed by Placebo

DRUG

Placebo then N-acetyl cysteine

Subject will receive Placebo first followed by N-acetyl cysteine

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Mark Steele, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03720483 on ClinicalTrials.gov